Compare Summit Therapeutics Inc (SMMT) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vipshop Holdings Ltd - ADR — how do they compare? Summit Therapeutics Inc trades at $15.18 (market cap $12.06B), while Vipshop Holdings Ltd - ADR trades at $14.45 (market cap $7.20B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VIPS | |
|---|---|---|
Market Cap | $12.06B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.98 | $20.68 |
52-Week Low | $12.55 | $12.92 |
Enterprise Value | $11.39B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
VIPS stock trades at $14.31, down 7.14% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.68, meeting expectations, and maintains strong profitability with a net income margin of 7.07%. Recent news highlights growth initiatives, including an outlet strategy to boost performance amid industry challenges.
The outlook for VIPS is cautiously optimistic, supported by low valuation multiples like a P/E of 6.79 and a buy consensus from 53.57% of analysts. Risks include revenue stagnation and macroeconomic pressures, but the stock's discounted valuation may offer upside if growth resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
